JNCI Journal of the National Cancer Institute最新文献

{"title":"Response to Orlandi.","authors":"Paolo Tarantino, Do Lee, Pamela R Soulos, Sarah Sammons, Maryam Lustberg","doi":"10.1093/jnci/djaf320","DOIUrl":"10.1093/jnci/djaf320","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"187-188"},"PeriodicalIF":7.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145477043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world vs unreal eligibility.","authors":"Howard S Hochster","doi":"10.1093/jnci/djaf292","DOIUrl":"10.1093/jnci/djaf292","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"10-11"},"PeriodicalIF":7.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RE: Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer.","authors":"Armando Orlandi","doi":"10.1093/jnci/djaf319","DOIUrl":"10.1093/jnci/djaf319","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"185-186"},"PeriodicalIF":7.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145477026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accelerometer-derived concentrated physical activity pattern and mortality in cancer survivors: the UK Biobank accelerometry study.","authors":"Haoting Shi, Zheshen Han, Qing Qu, Jingxuan Huang, Ruixin Pan, Jing Yu, Chao Hu, Qiaoge Chi, Shi Zhao, Jinliang Wang, Xiaosong Chen, Kunwei Shen, Rong Cai","doi":"10.1093/jnci/djaf146","DOIUrl":"10.1093/jnci/djaf146","url":null,"abstract":"<p><p>Although reduced mortality associated with moderate-to-vigorous physical activity has been reported among cancer survivors, the benefits of a concentrated physical activity pattern remain unclear. This prospective cohort study included 6075 cancer survivors from the UK Biobank accelerometry dataset: 2390 (39.3%) were inactive (<150 minutes/week), 1295 (21.3%) were active concentrated (≥150 minutes/week and achieved ≥50% total moderate-to-vigorous physical activity within 1-2 days), and 2390 (39.3%) were active regular (≥150 minutes/week but other than concentrated). After a median follow-up of 8 years (interquartile range [IQR] = 7.5 to 8.5 years), 634 deaths occurred. Active concentrated and regular patterns were associated with similar reduced all-cause mortality (hazard ratio [HR] = 0.72, 95% CI = 0.60 to 0.86; HR = 0.71, 95% CI = 0.56 to 0.89) and noncancer mortality (HR = 0.66, 95% CI = 0.47 to 0.92; HR = 0.56, 95% CI = 0.35 to 0.89). These findings highlight the concentrated physical activity pattern as a lifestyle intervention for cancer survivors.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"170-174"},"PeriodicalIF":7.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stat Bite: Productivity losses from premature cancer mortality in 2022.","authors":"Yek-Ching Kong, Freddie Bray, Isabelle Soerjomataram","doi":"10.1093/jnci/djaf330","DOIUrl":"10.1093/jnci/djaf330","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":"118 1","pages":"189-190"},"PeriodicalIF":7.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145952029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liquid biopsy for very early detection of HPV-associated oropharyngeal cancer.","authors":"David M Routman, Axel M Hidalgo, Aadel A Chaudhuri","doi":"10.1093/jnci/djaf302","DOIUrl":"10.1093/jnci/djaf302","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"7-9"},"PeriodicalIF":7.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12794210/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145488745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stat Bite: cumulative risk of cancer incidence and mortality in 2022.","authors":"Freddie Bray, Mathieu Laversanne","doi":"10.1093/jnci/djaf293","DOIUrl":"10.1093/jnci/djaf293","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":"117 12","pages":"2701-2702"},"PeriodicalIF":7.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145701003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tattooing and risk of melanoma: a population-based case-control study in Utah.","authors":"Rachel D McCarty, Britton Trabert, Lindsay J Collin, Morgan M Millar, David Kriebel, Laurie Grieshober, Mollie E Barnard, Jenna Sawatzki, Marjorie Carter, Valerie Yoder, Jeffrey A Gilreath, Douglas Grossman, John Hyngstrom, Paul J Shami, Jennifer A Doherty","doi":"10.1093/jnci/djaf235","DOIUrl":"10.1093/jnci/djaf235","url":null,"abstract":"<p><strong>Background: </strong>Tattooing can deliver carcinogens directly into the skin and cause immunological responses, and yet the relationship between tattooing and melanoma risk is unknown.</p><p><strong>Methods: </strong>In a population-based case-control study with 1167 melanoma cases (566 in situ; 601 invasive) and 5835 frequency-matched controls, we examined tattooing and melanoma risk using multivariable logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs).</p><p><strong>Results: </strong>Although ever receiving a tattoo was not strongly associated with melanoma risk, heavier tattooing exposure was associated with decreased risk. Overall melanoma risk was decreased among individuals who had received 4 or more tattoo sessions (OR = 0.44, 95% CI = 0.27 to 0.67) and individuals who had 3 or more large tattoos (OR = 0.26, 95% CI = 0.10 to 0.54) compared with those who were never tattooed. Invasive melanoma risk was also decreased among individuals who received their first tattoo before age 20 (OR = 0.48, 95% CI = 0.29 to 0.82) compared with never tattooed individuals.</p><p><strong>Conclusions: </strong>Our findings suggest that more tattoo exposure is associated with reduced melanoma risk, which does not support previously hypothesized associations between tattooing and increased melanoma risk. Unmeasured confounding is likely to contribute to our findings because we were not able to control for important melanoma risk factors. Potential causes of these associations could include sun exposure-related behaviors or immune responses to tattooing. Further investigation is warranted to clarify these relationships.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"2495-2504"},"PeriodicalIF":7.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12404683/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contrasts in colorectal cancer incidence and mortality in screening trials of sigmoidoscopy vs the Nordic-European Initiative on Colorectal Cancer colonoscopy trial.","authors":"Reinier G S Meester, Eric A Miller, Paul F Pinsky, Robert E Schoen, Uri Ladabaum","doi":"10.1093/jnci/djaf269","DOIUrl":"10.1093/jnci/djaf269","url":null,"abstract":"<p><strong>Background: </strong>Interim 10-year results from the Nordic-European Initiative on Colorectal Cancer (NordICC), a randomized controlled trial (RCT) of screening colonoscopy, demonstrated a statistically significant reduction in colorectal cancer (CRC) incidence but not mortality, contrary to results from 4 flexible sigmoidoscopy RCTs.</p><p><strong>Methods: </strong>We constructed CRC incidence and mortality Kaplan-Meier curves through 10 years to standardize comparisons across RCTs and examined CRC screen detection and stage. Novel analyses of 1 flexible sigmoidoscopy RCT (Prostate, Lung, Colorectal, and Ovarian cancer screening trial [PLCO]) assessed year-by-year mortality in screen-detected CRCs.</p><p><strong>Results: </strong>At 10 years, all RCTs demonstrated statistically significant CRC incidence reductions with screening (ratio = 0.77, 95% confidence interval [CI] = 0.70 to 0.84, to ratio = 0.82, 95% CI = 0.69 to 0.97, vs control arm; P ≤ .011). Two flexible sigmoidoscopy RCTs and NordICC showed no statistically significant CRC mortality reduction (ratio = 0.84, 95% CI = 0.64 to 1.10, to ratio = 0.90, 95% CI = 0.69 to 1.18; P = .10-0.23). In 3 flexible sigmoidoscopy RCTs and NordICC, relative reductions were greater in CRC incidence than CRC mortality, but only NordICC reported higher CRC mortality with screening vs the control arm for the first 7 years. In contrast, PLCO observed fewer CRC deaths with screening by year 2 (ratio = 0.59; P = .03), and screen-detected CRCs were less often advanced (odds ratio = 0.26; P < .001) or fatal (ratio = 0.50; P < .001).</p><p><strong>Conclusions: </strong>After 10 years, NordICC is similar to 2 flexible sigmoidoscopy RCTs in observing statistically significant reductions in CRC incidence but not CRC mortality. However, only NordICC observed greater CRC mortality with screening vs the control arm for 7 years. Granular analyses of CRC cases and deaths in NordICC, paralleling our PLCO analyses, could provide insight into why CRC mortality results differ in NordICC vs flexible sigmoidoscopy RCTs.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"2571-2579"},"PeriodicalIF":7.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12682369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk models of cancer-related cognitive complaints among early breast cancer survivors in the CANTO cohort.","authors":"Daniele Presti, Antonio Di Meglio, Julie Havas, Martina Pagliuca, Bianca Cheaib, Anne-Laure Martin, Catherine Gaudin, Christelle Jouannaud, Marion Fournier, Anne Kieffer, Mario Campone, Florence Lerebours, Thierry Petit, Sandrine Boyault, Aurelie Bertaut, Olivier Tredan, Francois Cherifi, Marie Lange, Caroline Pradon, Ines Vaz-Luis, Florence Joly","doi":"10.1093/jnci/djaf256","DOIUrl":"10.1093/jnci/djaf256","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) survivors receiving adjuvant treatments often report clinically relevant cancer-related cognitive complaints (CRCC), which have a significant impact on quality of life. We aimed to develop a comprehensive model of prediction of CRCC, including clinical and serum inflammatory protein data.</p><p><strong>Methods: </strong>We included 9575 stage I-III BC patients from the CANTO cohort (NCT01993498). Data were collected at diagnosis, 2 (year-2), and 4 (year-4) years post-diagnosis. Outcome of interest was CRCC (cognitive dimension of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 questionnaire, score < 75/100) at year-2 and year-4. Serum inflammatory markers (IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IFNg, IL-1, IL1Ra, TNF-a, and CRP) were available in a subset of patients with hormone-receptor-positive BC. Multivariable logistic regression models assessed associations of baseline clinical and inflammatory variables with CRCC.</p><p><strong>Results: </strong>Rates of CRCC were 31% (diagnosis), 39% (year-2), and 37% (year-4). Baseline validated predictors of CRCC reported at year-2 were chemotherapy, pretreatment CRCC, pain, and fatigue; predictors of CRCC reported at year-4 were pretreatment CRCC, pain, and anxiety. Other clinically relevant factors associated with CRCC at both time points during model development were pretreatment insomnia, receipt of endocrine therapy, and younger age/premenopausal status. No significant associations were observed between inflammatory markers and CRCC.</p><p><strong>Conclusions: </strong>Approximately 1 in 3 BC survivors in this cohort reported CRCC at diagnosis, with this rate being stable until year-4 after diagnosis. Pretreatment symptom burden and chemotherapy were validated as risk factors for long-term CRCC. No associations between inflammatory markers and self-reported CRCC emerged from this study.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"2535-2544"},"PeriodicalIF":7.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}